National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost-effectiveness of denosumab (Xgeva®) for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
15/08/2011 08/12/2011 Reimbursement Recommended

We consider denosumab (Xgeva®) a cost-effective therapy for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the Irish healthcare setting.

 Denosumab (Xgeva®) summary